Clinical trial / 2020
Weekly oral fecal microbiota transplantation from lean donors did not significantly improve insulin sensitivity or body composition in adults with obesity.
In a 12-week pilot trial, 24 adults with obesity and mild-moderate insulin resistance were randomized to weekly oral FMT capsules from healthy lean donors or placebo for 6 weeks. There were no statistically significant improvements in insulin sensitivity between groups (+5% ± 12% in FMT vs -3% ± 32% in placebo, mean difference 9%, 95% CI -5% to 28%, p = 0.16). Additionally, no significant differences were seen for HOMA-IR (mean difference 0.2, 95% CI -0.9 to 0.9, p = 0.96), lean mass (mean difference -0.1 kg, p = 0.87), or fat mass (mean difference 1.2 kg, p = 0.18). Variable bacterial engraftment persisted throughout 12 weeks with no serious adverse events related to FMT.
- Study type
- Randomized double-blind placebo-controlled pilot trial
- Who was studied
- 24 adults with obesity and mild-moderate insulin resistance
- What was measured
- Change in insulin sensitivity (hyperinsulinemic euglycemic clamps) and metabolic markers
THE PAPER
Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial.
Yu EW, Gao L, Stastka P, Cheney MC, Mahabamunuge J, Torres Soto M, Ford CB, Bryant JA, Henn MR, Hohmann EL. PLoS Med, 2020.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.